Endocrine-disrupting chemicals: economic, regulatory, and policy implications - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue The Lancet. Diabetes & Endocrinology Année : 2020

Endocrine-disrupting chemicals: economic, regulatory, and policy implications

Résumé

Endocrine-disrupting chemicals (EDCs) substantially cost society as a result of increases in disease and disability but—unlike other toxicant classes such as carcinogens—have yet to be codified into regulations as a hazard category. This Series paper examines economic, regulatory, and policy approaches to limit human EDC exposures and describes potential improvements. In the EU, general principles for EDCs call for minimisation of human exposure, identification as substances of very high concern, and ban on use in pesticides. In the USA, screening and testing programmes are focused on oestrogenic EDCs exclusively, and regulation is strictly risk-based. Minimisation of human exposure is unlikely without a clear overarching definition for EDCs and relevant pre-marketing test requirements. We call for a multifaceted international programme (eg, modelled on the International Agency for Research in Cancer) to address the effects of EDCs on human health—an approach that would proactively identify hazards for subsequent regulation.

Dates et versions

inserm-03176803 , version 1 (22-03-2021)

Identifiants

Citer

Christopher Kassotis, Laura Vandenberg, Barbara Demeneix, Miquel Porta, Rémy Slama, et al.. Endocrine-disrupting chemicals: economic, regulatory, and policy implications. The Lancet. Diabetes & Endocrinology , 2020, 8 (8), pp.719-730. ⟨10.1016/S2213-8587(20)30128-5⟩. ⟨inserm-03176803⟩
38 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More